332 related articles for article (PubMed ID: 25531529)
1. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
Song L; Yang MC; Knoff J; Wu TC; Hung CF
PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy using a potent immunodominant CTL epitope.
Song L; Yang MC; Knoff J; Sun ZY; Wu TC; Hung CF
Vaccine; 2014 Oct; 32(46):6039-48. PubMed ID: 25245934
[TBL] [Abstract][Full Text] [Related]
3. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
4. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell.
Kim D; Hoory T; Wu TC; Hung CF
Hum Gene Ther; 2007 Nov; 18(11):1129-39. PubMed ID: 17939748
[TBL] [Abstract][Full Text] [Related]
5. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency.
Hung CF; Tsai YC; He L; Wu TC
Mol Ther; 2007 Jun; 15(6):1211-9. PubMed ID: 17356542
[TBL] [Abstract][Full Text] [Related]
7. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
Kim D; Monie A; He L; Tsai YC; Hung CF; Wu TC
Gene Ther; 2008 May; 15(9):677-87. PubMed ID: 18273057
[TBL] [Abstract][Full Text] [Related]
8. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation.
Wu CY; Monie A; Pang X; Hung CF; Wu TC
J Biomed Sci; 2010 Nov; 17(1):88. PubMed ID: 21092195
[TBL] [Abstract][Full Text] [Related]
9. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.
Wu A; Zeng Q; Kang TH; Peng S; Roosinovich E; Pai SI; Hung CF
Gene Ther; 2011 Mar; 18(3):304-12. PubMed ID: 20981112
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
Kim D; Hoory T; Monie A; Ting JP; Hung CF; Wu TC
J Immunol; 2008 May; 180(10):7019-27. PubMed ID: 18453624
[TBL] [Abstract][Full Text] [Related]
11. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
12. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
[TBL] [Abstract][Full Text] [Related]
15. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice.
Kim D; Monie A; Tsai YC; He L; Wang MC; Hung CF; Wu TC
Gene Ther; 2008 Aug; 15(16):1176-83. PubMed ID: 18463686
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
18. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
Front Immunol; 2021; 12():803090. PubMed ID: 35003132
[TBL] [Abstract][Full Text] [Related]
19. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
[TBL] [Abstract][Full Text] [Related]
20. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism.
Cheng WF; Chang MC; Sun WZ; Lee CN; Lin HW; Su YN; Hsieh CY; Chen CA
Gene Ther; 2008 Jul; 15(13):1007-16. PubMed ID: 18356819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
